GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Total Long-Term Liabilities

Scinopharm Taiwan (TPE:1789) Total Long-Term Liabilities : NT$639 Mil (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Scinopharm Taiwan Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Scinopharm Taiwan's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was NT$639 Mil.

Scinopharm Taiwan Total Long-Term Liabilities Historical Data

The historical data trend for Scinopharm Taiwan's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinopharm Taiwan Total Long-Term Liabilities Chart

Scinopharm Taiwan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 630.71 623.81 658.03 627.70 649.25

Scinopharm Taiwan Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 654.95 651.17 650.36 649.25 639.29

Scinopharm Taiwan Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Scinopharm Taiwan Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Scinopharm Taiwan's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinopharm Taiwan Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scinopharm Taiwan Ltd (TPE:1789) » Definitions » Total Long-Term Liabilities
Comparable Companies
ROCO:6620 ROCO:4114 TPE:3705 TPE:1720 ROCO:6576 ROCO:4105 ROCO:6785 TPE:4119 TPE:4746 TPE:1707 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Website
https://www.scinopharm.com
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. The company also conducts consulting and technical services. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.

Scinopharm Taiwan Headlines

No Headlines